Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

In this video, Jeff Yu, MD, MS, emphasized the importance of chronic hand eczema awareness and highlighted a study on the causes and treatments of the disease, presented at the Revolutionizing Atopic ...

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

About 15% of children in the United States develop atopic dermatitis. Almost all these pediatric patients are diagnosed by age 5, but more than half develop atopic dermatitis or "eczema" in the ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

The Many Ways to Measure the Severity of Atopic Dermatitis — Validated physician-reported tools are often complicated, but patient-based measures are easy and informative ...

Atopic dermatitis is the most common type of eczema and affects ~16.5 million adults and 9.6 million children in the US. The ...

Investing.com -- Apogee (NASDAQ: APOG) Therapeutics, Inc. (NASDAQ: APGE) stock surged 24% on Monday after the clinical-stage biotechnology company announced positive 16-week data from its Phase 2 APEX ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Nektar Therapeutics (NASDAQ:NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar ...